Epizyme Inc Drug Patent Portfolio

Epizyme Inc owns 1 orange book drug protected by 24 US patents Given below is the list of Epizyme Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10786511 Method for treating cancer 19 Dec, 2035
Active
US10369155 Method for treating cancer 16 Oct, 2035
Active
US9889138 Method for treating cancer 16 Oct, 2035
Active
US9688665 Methods of treating cancer 22 Aug, 2034
Active
US8410088 Aryl- or heteroaryl-substituted benzene compounds 23 Jan, 2034
Active
US10245269 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
Active
US10821113 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
Active
US11491163 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
Active
US9394283 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
Active
US9872862 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
Active
US11052093 Aryl-or heteroaryl-substituted benzene compounds 13 Apr, 2032
Active
US9522152 Aryl- or heteroaryl-substituted benzene compounds 13 Apr, 2032
Active
US10155002 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
Active
US10420775 Aryl-or heteroaryl-substituted benzene compounds 12 Sep, 2031
Active
US8691507 Inhibitors of human EZH2 and methods of use thereof 12 Sep, 2031
Active
US8765732 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
Active
US8895245 Inhibitors of human EZH2 and methods of use thereof 12 Sep, 2031
Active
US9090562 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
Active
US9175331 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
Active
US9333217 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
Active
US9334527 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
Active
US9549931 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
Active
US9855275 Aryl-or heteroaryl-substituted benzene compounds 12 Sep, 2031
Active
US9949999 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
Active


Given below is the list of recent legal activities going on the following drug patents of Epizyme Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jul, 2024 US9549931
Patent eCofC Notification 11 Jun, 2024 US9394283
Mail Patent eCofC Notification 11 Jun, 2024 US9394283
Email Notification 11 Jun, 2024 US9394283
Recordation of Patent eCertificate of Correction 11 Jun, 2024 US9394283
Payment of Maintenance Fee, 8th Year, Large Entity 05 Jun, 2024 US9522152
Payment of Maintenance Fee, 4th Year, Large Entity 17 Apr, 2024 US10821113
Email Notification 17 Apr, 2024 US9889138
Email Notification 16 Apr, 2024 US9889138
Mail Patent eCofC Notification 16 Apr, 2024 US9889138
Recordation of Patent eCertificate of Correction 16 Apr, 2024 US9889138
Patent eCofC Notification 16 Apr, 2024 US9889138
Change in Power of Attorney (May Include Associate POA) 11 Apr, 2024 US8895245
Email Notification 11 Apr, 2024 US8895245
Change in Power of Attorney (May Include Associate POA) 10 Apr, 2024 US8410088


Epizyme Inc Drug Patents' Oppositions Filed in EPO

Epizyme Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 02, 2016, by Glaxosmithkline Intellectual Property (No.2) Limited. This opposition was filed on patent number EP11824247A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11824247A Nov, 2016 GlaxoSmithKline Intellectual Property (No.2) Limited Granted and Under Opposition


Epizyme Inc's Family Patents

Epizyme Inc drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 20.2% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Epizyme Inc Drug List

Given below is the complete list of Epizyme Inc's drugs and the patents protecting them.


1. Tazverik

Tazverik is protected by 24 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10786511 Method for treating cancer 19 Dec, 2035
(11 years from now)
Active
US10369155 Method for treating cancer 16 Oct, 2035
(11 years from now)
Active
US9889138 Method for treating cancer 16 Oct, 2035
(11 years from now)
Active
US9688665 Methods of treating cancer 22 Aug, 2034
(9 years from now)
Active
US8410088 Aryl- or heteroaryl-substituted benzene compounds 23 Jan, 2034
(9 years from now)
Active
US10245269 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
(8 years from now)
Active
US10821113 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
(8 years from now)
Active
US11491163 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
(8 years from now)
Active
US9394283 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
(8 years from now)
Active
US9872862 Salt form of a human histone methyltransferase EZH2 inhibitor 11 Apr, 2033
(8 years from now)
Active
US11052093 Aryl-or heteroaryl-substituted benzene compounds 13 Apr, 2032
(7 years from now)
Active
US9522152 Aryl- or heteroaryl-substituted benzene compounds 13 Apr, 2032
(7 years from now)
Active
US10155002 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
(6 years from now)
Active
US10420775 Aryl-or heteroaryl-substituted benzene compounds 12 Sep, 2031
(6 years from now)
Active
US8691507 Inhibitors of human EZH2 and methods of use thereof 12 Sep, 2031
(6 years from now)
Active
US8765732 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
(6 years from now)
Active
US8895245 Inhibitors of human EZH2 and methods of use thereof 12 Sep, 2031
(6 years from now)
Active
US9090562 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
(6 years from now)
Active
US9175331 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
(6 years from now)
Active
US9333217 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
(6 years from now)
Active
US9334527 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
(6 years from now)
Active
US9549931 Aryl- or heteroaryl-substituted benzene compounds 12 Sep, 2031
(6 years from now)
Active
US9855275 Aryl-or heteroaryl-substituted benzene compounds 12 Sep, 2031
(6 years from now)
Active
US9949999 Inhibitors of human EZH2, and methods of use thereof 12 Sep, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tazverik's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List